High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
192.78M
+15.06%
0.444
+0.85%
191.51M
+13.21%
0.447
+14.68%
204.46M
+12.12%
0.502
+35.74%
Estimates Revision
The market is revising Upward the revenue expectations for Repligen Corporation (RGEN) for FY2025, with the revenue forecasts being adjusted by 0.9% over the past three months. During the same period, the stock price has changed by 33.08%.
Revenue Estimates for FY2025
Revise Upward
+0.9%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.99%
In Past 3 Month
Stock Price
Go Up
+33.08%
In Past 3 Month
15 Analyst Rating
Wall Street analysts forecast RGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGEN is 183.36 USD with a low forecast of 135.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
4 Hold
0 Sell
Moderate Buy
Current: 165.760
Low
135.00
Averages
183.36
High
220.00
Current: 165.760
Low
135.00
Averages
183.36
High
220.00
Barclays
Overweight
maintain
$160 -> $175
2025-10-29
Reason
Barclays
Price Target
$160 -> $175
2025-10-29
maintain
Overweight
Reason
Barclays raised the firm's price target on Repligen to $175 from $160 and keeps an Overweight rating on the shares following the earnings report. The company's outlook downshift or next year is driven by a lower market growth outlook based on peer commentary, but there is potential upside, the analyst tells investors in a research note.
Canaccord
Hold
maintain
$150 -> $165
2025-10-29
Reason
Canaccord
Price Target
$150 -> $165
2025-10-29
maintain
Hold
Reason
Canaccord raised the firm's price target on Repligen to $165 from $150 and keeps a Hold rating on the shares. The firm raised estimates given the 3Q25 revenue beat and relatively improving biopharma outlook as the company reported 3Q25 results that were ahead of estimates while the company achieved revenue growth across all franchises led by Process Analytics.
HSBC
NULL -> Buy
initiated
$150
2025-10-01
Reason
HSBC
Price Target
$150
2025-10-01
initiated
NULL -> Buy
Reason
HSBC initiated coverage of Repligen with a Buy rating and $150 price target. While biotech funding and the regulatory environment are headwinds for the company, its volume leverage in a recovery is underappreciated, the analyst tells investors in a research note. The firm believes Repligen's portfolio in bioprocessing can drive double-digit revenue growth.
Evercore ISI
In Line
to
Outperform
upgrade
$130 -> $155
2025-09-22
Reason
Evercore ISI
Price Target
$130 -> $155
2025-09-22
upgrade
In Line
to
Outperform
Reason
Evercore ISI upgraded Repligen to Outperform from In Line with a price target of $155, up from $130. The firm believes the bioprocessing solutions end market is "relatively insulated" from macro headwinds and is now back now back to a normal high-single-digit growth cadence. Evercore believes Repligen's new business is delivering while its new modalities overhang "is seemingly removed."
RBC Capital
Outperform
maintain
$204 -> $205
2025-09-02
Reason
RBC Capital
Price Target
$204 -> $205
2025-09-02
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Repligen to $205 from $204 and keeps an Outperform rating on the shares as part of a broader research note on the Life Sciences Tools and Diagnostics sector. The firm is updating its model with "more realistic" multiples, the analyst tells investors in a research note. RBC added however that Repligen plays in some of the fastest-growing markets in the sector, driving 20% organic growth annually from 2020 to 2022, which is "well above peers". Slowdowns caused by elevated customer inventories and other macro headwinds caused revenue to slow in recent quarters, but RBC believes revenue will re-accelerate throughout FY25 as headwinds dissipate, the firm stated.
Stephens
Steven Etoch
initiated
$160
2025-07-21
Reason
Stephens
Steven Etoch
Price Target
$160
2025-07-21
initiated
Reason
Stephens analyst Steven Etoch resumed coverage of Repligen with an Overweight rating and $160 price target. The firm views Repligen as the leader within the bioprocessing industry. It faces industry tailwinds from the increase in the late stage pipeline of biologics and biosimilars entering the market continue which continue to drive an increasing need for bioprocessing capabilities, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Repligen Corp (RGEN.O) is 86.34, compared to its 5-year average forward P/E of 84.19. For a more detailed relative valuation and DCF analysis to assess Repligen Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
84.19
Current PE
86.34
Overvalued PE
104.14
Undervalued PE
64.23
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
56.80
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
71.29
Undervalued EV/EBITDA
42.32
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
14.05
Current PS
0.00
Overvalued PS
17.44
Undervalued PS
10.67
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 143.49% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 143.49% over the last month.
Sold
Bought
RGEN News & Events
Events Timeline
(ET)
2025-10-28
07:36:15
Repligen projects FY25 adjusted EPS between $1.65 and $1.68, slightly below consensus of $1.69.
2025-10-28
07:34:52
Repligen announces Q3 adjusted earnings per share of 46 cents, surpassing consensus estimate of 42 cents.
2025-10-13 (ET)
2025-10-13
10:07:37
Canaccord Questions Repligen Approval Following Novo Nordisk Update
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/300e3979538679577717cac4426b530ebf85456a5c025910950f823d9aaa086e.png)
Preview
6.0
10-30BenzingaCanaccord Genuity Keeps Hold Rating on Repligen and Increases Price Target to $165
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/911e99bc5401740dd93e0e58afd9cb404ee80bfb1fde94a6433b6aabddfd54f9.jpg)
Preview
9.5
10-28NASDAQ.COMRepligen (RGEN) Exceeds Expectations in Q3 Earnings and Revenue
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/fdeeff64a34e0a93c75d7816de790e38f7e455716fc8f2cff32ca1862e2e4714.jpg)
Preview
6.5
10-28NASDAQ.COMAnalysts Predict 10% Growth Potential for PTL
Sign Up For More News
People Also Watch
FAQ
What is Repligen Corp (RGEN) stock price today?
What is Repligen Corp (RGEN)'s business?
What is the price predicton of RGEN Stock?
What is Repligen Corp (RGEN)'s revenue for the last quarter?
What is Repligen Corp (RGEN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Repligen Corp (RGEN)'s fundamentals?
How many employees does Repligen Corp (RGEN). have?